drugset

drugset / Trial / NCT03153410

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

NCT03153410 ↗

Phase 0 Completed 11 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Eli Lilly and Company · collab Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.

Timeline

Start: 2018-09-27
Primary completion: 2022-03-09
Completion: 2023-08-29

Publications

Urman A, Ding Y, Durham J, Wang H, Qi H, Narang A, Burkhart R, He J, Le D, Laheru D, Thompson E, Jaffee E, Purtell K, Waisome-Stephens C, Liu M, Zheng L, De Jesus-Acosta A. Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Front Immunol. 2026 Mar 9;17:1715761. doi: 10.3389/fimmu.2026.1715761. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	200 mg/m2	Intravenous
Subject	GVAX Pancreas Vaccine (GVAX)	Vaccine	5e+08 cells	Other
Subject	IMC-CS4	Monoclonal antibody	75 mg	Intravenous
Subject	IMC-CS4	Monoclonal antibody	100 mg	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

Indications